Clinical Trial Update: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) [Phase 2]

View source ↗

Summary

Phase 2 trial update on Tecartus (brexucabtagene autoleucel) for relapsed/refractory mantle cell lymphoma; Cohorts 1 and 2 completed with results posted in 2020…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Tecartus (brexucabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-10